ATLASAlnylam Pharmaceuticals (ALNY) Q3 2026 earnings results
Alnylam Pharmaceuticals (ALNY) reported EPS of $15.72 against an analyst estimate of $1.46: a beat of $14.26 (976.7%). The quarter ended Sep 30, 2026; the company reported on Thursday, October 29, 2026, before the open.
Status: Confirmed · cross-checked Nov 2 · Source: EODHD (calendar and fundamentals, cross-checked)
Notify me when Alnylam Pharmaceuticals reports
Track ALNY free Add Alnylam Pharmaceuticals to a free ATLAS watchlist.
ALNY Q3 2026 results at a glance
| EPS reported | $15.72 |
|---|---|
| EPS estimate | $1.46 |
| Surprise | Beat · +$14.26 (+976.7%) |
| Quarter ended | Sep 30, 2026 |
| Reported | Oct 29, 2026, before the open |
| Status | Confirmed · cross-checked Nov 2 |
EPS is as supplied by EODHD, in US dollars per share; whether it is adjusted or GAAP follows that source. This is Alnylam Pharmaceuticals’s Q3 2026, a calendar-year company.
Alnylam Pharmaceuticals EPS surprise history: last 5 quarters
Alnylam Pharmaceuticals beat the EPS estimate in 3 of its last 5 reports, with an average surprise of +209.4%.
| Report date | EPS est. | EPS actual | Surprise | Result | Move* |
|---|---|---|---|---|---|
| Oct 29, 2026 | $1.46 | $15.72 | +976.7% | Beat | – |
| Jul 30, 2026 | $2.14 | $1.84 | -14.0% | Miss | -28.3% |
| Apr 30, 2026 | $1.47 | $1.99 | +35.4% | Beat | -1.7% |
| Feb 12, 2026 | $1.50 | $1.25 | -16.7% | Miss | -2.5% |
| Oct 30, 2025 | $1.75 | $2.90 | +65.7% | Beat | -5.3% |
*Move: change in the closing price from the last close before the report day to the close the day after it. It is filled in a few trading days after each report.
ALNY stock reaction to the report
ALNY moved -25.13% in the first session that reflects the report (close of Oct 28, 2026 $232.40 to close of Oct 29, 2026 $174.00). Since the report: -32.01% (latest close $158.00 on Nov 2, 2026, against $232.40 before the reaction).
Next ALNY earnings report
Alnylam Pharmaceuticals has not announced its next earnings date yet. This page shows a date only once it is confirmed. See the ALNY earnings calendar.
ATLAS fair value and signal for ALNY
| Last price | $158.00 (-4.2%) |
|---|---|
| ATLAS fair value | $227.28 (range $157.55–$327.88) · price is 30% below it |
| Chance of a higher close in 1 month | 44% (normal range $127.01–$181.72) |
These are model outputs from the same valuation and calibrated model as the Alnylam Pharmaceuticals stock page. They describe an ordinary period and are not a forecast of any particular outcome.
Alnylam Pharmaceuticals Q3 2026 earnings: frequently asked questions
Did Alnylam Pharmaceuticals beat earnings estimates for Q3 2026?
Alnylam Pharmaceuticals reported EPS of $15.72 against an analyst estimate of $1.46: a beat of $14.26 (976.7%).
When did Alnylam Pharmaceuticals report Q3 2026 results?
Alnylam Pharmaceuticals reported on Thursday, October 29, 2026, before the open, for the quarter ended Wednesday, September 30, 2026.
How often does ALNY beat EPS estimates?
In its last 5 reports with a recorded result, Alnylam Pharmaceuticals beat the EPS estimate 3 times; the average surprise was +209.4%. Past results do not predict the next one.
How does ATLAS confirm a result?
A result is published only after it is cross-checked: the EODHD earnings calendar and the EODHD fundamentals feed must show the same EPS for the same fiscal period, or the same value must appear in two consecutive checks. Unconfirmed figures are never published. If the figures are revised later, this page updates.
Educational information, not investment advice. Disclaimer